October 2021 OSE Immunotherapeutics Partners with GERCOR to Conduct a Combination Phase 2 Trial of Tedopi®
October 2021 OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127
October 2021 OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York
October 2021 Selexis SA and OSE Immunotherapeutics Sign Commercial License Agreement to Further Advance Development of OSE’s Interleukin Receptor 7 Antagonist
October 2021 OSE Immunotherapeutics Strengthens R&D Team with Appointment of Two Senior Talented Immunologists